Lack of correlation between 1,5-anhydro glucitol assay and oral glucose tolerance test in patients with cystic fibrosis

Endocrine Practice

Volumn 16, Issue 2, 2010, Pages 167-170

  Kinnaird, Kate E H ^a   Sauerwein, Tom J ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; 1,5-ANHYDROGLUCITOL; DEOXYGLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES MELLITUS; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE; ORAL GLUCOSE TOLERANCE TEST; PILOT STUDY; SCREENING TEST; BLOOD; GLUCOSE TOLERANCE TEST; METABOLISM;

ADULT; BLOOD GLUCOSE; CYSTIC FIBROSIS; DEOXYGLUCOSE; FEMALE; FRUCTOSAMINE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; YOUNG ADULT;

EID: 77953935733     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09149.OR     Document Type: Article

References (27)

1. Costa M, Potvin S, Berthiaume Y, et al. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab. 2005;31(3, pt 1):221-232. (Pubitemid 40961519)
2. Lanng S. Glucose intolerance in cystic fibrosis patients. Paediatr Respir Rev. 2001;2:253-259. (Pubitemid 34460746)
3. Rosenecker J, Höfler R, Steinkamp G, et al. Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome. Eur J Med Res. 2001;6:345-350.
4. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000;162(3, pt 1):891-895.
5. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005;146:681-687. (Pubitemid 40616255)
6. Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr. 1988;112:373-377. (Pubitemid 18079818)
7. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr. 1994;83:849-853. (Pubitemid 24281615)
8. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 1992;151:684-687.
9. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ. 1995;311:655-659.
10. Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros. 2004;3:209-222. (Pubitemid 40227489)
11. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus report. Diabetes Res Clin Pract. 1999;45:61-73. (Pubitemid 29356125)
12. Mueller-Brandes C, Holl RW, Nastoli M, Ballmann M. New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis. Eur Respir J. 2005;24:715-717. (Pubitemid 40528767)
13. Dungan KM, Buse JB, Largay J, et al. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006;29:1214-1219.
14. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark): a short term glycemic marker. Diabetes Technol Ther. 2003;5:355-363.
15. McGill JB, Cole TG, Nowatzke W, et al (U.S. Trial of the GlycoMark Assay). Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. Trial of the GlycoMark Assay. Diabetes Care. 2004;27:1859-1865.
16. Yamanouchi T, Tachibana Y, Akanuma H, et al. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol. 1992;263(2, pt 1):E268-E273.
17. Yamanouchi T, Akanuma H, Asano T, Konishi C, Akaoka I, Akanuma Y. Reduction and recovery of plasma 1,5-anhydro-D-glucitol level in diabetes mellitus. Diabetes. 1987;36:709-715. (Pubitemid 17141109)
18. Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract. 1994;24(suppl):S261-S268.
19. Kilpatrick ES, Keevilt BG, Richmond KL, Newland P, Addison GM. Plasma 1,5-anhydroglucitol concentrations are influenced by variation in the renal threshold for glucose. Diabet Med. 1999;16:496-499.
20. Emoto M, Tabata T, Inoue T, Nishizawa Y, Morii H. Plasma 1,5-anhydroglucitol concentration in patients with end-stage renal disease with and without diabetes. Nephron. 1992;61:181-186.
21. Yamagishi S, Ohta M. Serum 1,5-anhydro-D-glucitol levels in liver cirrhosis. Acta Diabetol. 1998;35:65-66. (Pubitemid 28306258)
22. Watanabe K, Uchino H, Ohmura C, Tanaka Y, Onuma T, Kawamori R. Different effects of two alpha-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level. J Diabetes Complications. 2004;18:183-186. (Pubitemid 38622549)
23. Nowatzke W, Sarno MJ, Birch NC, Stickle DF, Eden T, Cole TG. Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark) and determination of reference intervals on the Hitachi 917 analyzer. Clin Chim Acta. 2004;350:201-209. (Pubitemid 39458264)
24. Yamanouchi T, Akanuma Y, Toyota T, et al. Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes. 1991;40:52-57.
25. Robertson DA, Alberti KG, Dowse GK, Zimmet P, Tuomilehto J, Gareeboo H (Mauritius Noncommunicable Diseases Study Group). Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening? Diabet Med. 1993;10:56-60.
26. Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med. 2004;21:691-696. (Pubitemid 38916212)
27. Franzese A, Valerio G, Buono P, et al. Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. J Pediatr Endocrinol Metab. 2008;21:109-116. (Pubitemid 351454563)